In this episode, we address a growing concern within the addiction treatment sector regarding the proliferation of exaggerated success rate claims surrounding ibogaine therapy. Aeden Smith-Ahearn, founder of Experience Ibogaine, challenges recent media-driven narratives—including claims that suggest a near-total resolution of opioid dependence after one or two doses. Smith-Ahearn argues that such statistics are fundamentally misleading, as they fail to account for long-term relapse rates and the complex nature of sustained recovery. The discussion explores why these oversimplified success metrics are detrimental to patient care, leading to unrealistic expectations and a lack of necessary preparation for the post-treatment phase. Furthermore, the episode examines the broader industry implications of this misinformation. As demand fueled by sensationalized narratives rises, the market has seen an influx of new facilities implementing aggressive pricing structures and prioritizing profit over established clinical standards. By highlighting the reality of ibogaine treatment—where relapse remains a significant challenge—this episode advocates for greater transparency, ethical responsibility, and evidence-based practices in the field. Listeners gain a clearer understanding of the genuine role ibogaine plays in addiction recovery and why honest, comprehensive care must remain the primary focus for all reputable practitioners.

---
📰 Read the full press release
🌐 Visit https://www.experienceibogaine.com/